Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Bhatt’s study, "Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts,” was recently published in The New England Journal of Medicine. Bhatt and colleagues conducted a multicenter ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In those with and those without emphysema, patients ...

GSK has high hopes for Nucala thanks to its less frequent dosing – once a month, versus every other week for Dupixent – and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 BOREAS trial included adults with ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses improvements in lung function observed in patients enrolled in the BOREAS trial. The results of the BOREAS ...

Learn how air pollution causes COPD and affects lung health. Take important steps to improve indoor and outdoor air quality ...

This study, published in the journal Nature Communications, determined the mechanism of this live biotherapeutic product — a powder mixture of living Lactobacilli bacteria — to reduce neutrophilic ...

A new study shows that a form of vitamin B3 can reduce lung inflammation in COPD patients. The researchers hope it will pave the way for new treatment options. We live longer and longer, and as we age ...

Dupilumab significantly reduced exacerbations and improved lung function in adults with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation, based on data from more than ...

In recent years, research has revealed more about the factors underlying the pathogenesis of chronic obstructive pulmonary disease (COPD). In particular, inflammation in the lungs leads to the ...